Global Antisense Oligonucleotide Therapies 麻豆原创 Research Report 2023

Publication ID:

PB501233288

Publication Date:

January 12, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Highlights
The global Antisense Oligonucleotide Therapies market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Antisense Oligonucleotide Therapies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Antisense Oligonucleotide Therapies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Antisense Oligonucleotide Therapies in Genetic Disease is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Antisense Oligonucleotide Therapies include Ionis Pharmaceuticals, Sarepta Therapeutics and Nippon Shinyaku, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antisense Oligonucleotide Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antisense Oligonucleotide Therapies.
The Antisense Oligonucleotide Therapies market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Antisense Oligonucleotide Therapies market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antisense Oligonucleotide Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
Segment by Type
Without GalNAc-conjugated
With GalNAc-conjugated
Segment by Application
Genetic Disease
Cancer
Cardiovascular Diseases
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antisense Oligonucleotide Therapies companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Antisense Oligonucleotide Therapies 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Without GalNAc-conjugated
1.2.3 With GalNAc-conjugated
1.3 麻豆原创 by Application
1.3.1 Global Antisense Oligonucleotide Therapies 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Genetic Disease
1.3.3 Cancer
1.3.4 Cardiovascular Diseases
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antisense Oligonucleotide Therapies 麻豆原创 Perspective (2018-2029)
2.2 Antisense Oligonucleotide Therapies Growth Trends by Region
2.2.1 Global Antisense Oligonucleotide Therapies 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Antisense Oligonucleotide Therapies Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Antisense Oligonucleotide Therapies Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Antisense Oligonucleotide Therapies 麻豆原创 Dynamics
2.3.1 Antisense Oligonucleotide Therapies Industry Trends
2.3.2 Antisense Oligonucleotide Therapies 麻豆原创 Drivers
2.3.3 Antisense Oligonucleotide Therapies 麻豆原创 Challenges
2.3.4 Antisense Oligonucleotide Therapies 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antisense Oligonucleotide Therapies Players by Revenue
3.1.1 Global Top Antisense Oligonucleotide Therapies Players by Revenue (2018-2023)
3.1.2 Global Antisense Oligonucleotide Therapies Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Antisense Oligonucleotide Therapies 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antisense Oligonucleotide Therapies Revenue
3.4 Global Antisense Oligonucleotide Therapies 麻豆原创 Concentration Ratio
3.4.1 Global Antisense Oligonucleotide Therapies 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense Oligonucleotide Therapies Revenue in 2022
3.5 Antisense Oligonucleotide Therapies Key Players Head office and Area Served
3.6 Key Players Antisense Oligonucleotide Therapies Product Solution and Service
3.7 Date of Enter into Antisense Oligonucleotide Therapies 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Antisense Oligonucleotide Therapies Breakdown Data by Type
4.1 Global Antisense Oligonucleotide Therapies Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Antisense Oligonucleotide Therapies Forecasted 麻豆原创 Size by Type (2024-2029)
5 Antisense Oligonucleotide Therapies Breakdown Data by Application
5.1 Global Antisense Oligonucleotide Therapies Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Antisense Oligonucleotide Therapies Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Antisense Oligonucleotide Therapies 麻豆原创 Size (2018-2029)
6.2 North America Antisense Oligonucleotide Therapies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Antisense Oligonucleotide Therapies 麻豆原创 Size by Country (2018-2023)
6.4 North America Antisense Oligonucleotide Therapies 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antisense Oligonucleotide Therapies 麻豆原创 Size (2018-2029)
7.2 Europe Antisense Oligonucleotide Therapies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Antisense Oligonucleotide Therapies 麻豆原创 Size by Country (2018-2023)
7.4 Europe Antisense Oligonucleotide Therapies 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antisense Oligonucleotide Therapies 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Antisense Oligonucleotide Therapies 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Antisense Oligonucleotide Therapies 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Antisense Oligonucleotide Therapies 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antisense Oligonucleotide Therapies 麻豆原创 Size (2018-2029)
9.2 Latin America Antisense Oligonucleotide Therapies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Antisense Oligonucleotide Therapies 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Antisense Oligonucleotide Therapies 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antisense Oligonucleotide Therapies 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Antisense Oligonucleotide Therapies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Antisense Oligonucleotide Therapies 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Antisense Oligonucleotide Therapies 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Company Detail
11.1.2 Ionis Pharmaceuticals Business Overview
11.1.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Introduction
11.1.4 Ionis Pharmaceuticals Revenue in Antisense Oligonucleotide Therapies Business (2018-2023)
11.1.5 Ionis Pharmaceuticals Recent Development
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Detail
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Antisense Oligonucleotide Therapies Introduction
11.2.4 Sarepta Therapeutics Revenue in Antisense Oligonucleotide Therapies Business (2018-2023)
11.2.5 Sarepta Therapeutics Recent Development
11.3 Nippon Shinyaku
11.3.1 Nippon Shinyaku Company Detail
11.3.2 Nippon Shinyaku Business Overview
11.3.3 Nippon Shinyaku Antisense Oligonucleotide Therapies Introduction
11.3.4 Nippon Shinyaku Revenue in Antisense Oligonucleotide Therapies Business (2018-2023)
11.3.5 Nippon Shinyaku Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.